<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Russian Journal of Allergy</journal-id><journal-title-group><journal-title xml:lang="en">Russian Journal of Allergy</journal-title><trans-title-group xml:lang="ru"><trans-title>Российский Аллергологический Журнал</trans-title></trans-title-group></journal-title-group><issn publication-format="print">1810-8830</issn><issn publication-format="electronic">2686-682X</issn><publisher><publisher-name xml:lang="en">Publishing House ABV Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">16463</article-id><article-id pub-id-type="doi">10.36691/RJA16463</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>Original studies</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>Оригинальные исследования</subject></subj-group><subj-group subj-group-type="article-type"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">Changes in the avids of IgG antibodies to the S protein of SARS-CoV-2 after coronavirus infection in medical workers of a temporary infections hospital</article-title><trans-title-group xml:lang="ru"><trans-title>Изменение авидности IgG антител к S-белку SARS-CoV-2 после перенесённой коронавирусной инфекции у медицинских работников временного инфекционного госпиталя</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-3584-6861</contrib-id><name-alternatives><name xml:lang="en"><surname>Reshetnikova</surname><given-names>Irina D.</given-names></name><name xml:lang="ru"><surname>Решетникова</surname><given-names>Ирина Дмитриевна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD, Cand. Sci. (Med.), Associate Professor</p></bio><bio xml:lang="ru"><p>канд. мед. наук, доцент</p></bio><email>reshira@mail.ru</email><xref ref-type="aff" rid="aff1"/><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-2536-3604</contrib-id><name-alternatives><name xml:lang="en"><surname>Tyurin</surname><given-names>Yuri A.</given-names></name><name xml:lang="ru"><surname>Тюрин</surname><given-names>Юрий Александрович</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD, Dr. Sci. (Med.)</p></bio><bio xml:lang="ru"><p>д-р мед. наук</p></bio><email>tyurin.yurii@yandex.ru</email><xref ref-type="aff" rid="aff1"/><xref ref-type="aff" rid="aff3"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-4411-8786</contrib-id><name-alternatives><name xml:lang="en"><surname>Agafonova</surname><given-names>Elena V.</given-names></name><name xml:lang="ru"><surname>Агафонова</surname><given-names>Елена Валентиновна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD, Cand. Sci. (Med.)</p></bio><bio xml:lang="ru"><p>канд. мед. наук</p></bio><email>agafono@mail.ru</email><xref ref-type="aff" rid="aff1"/><xref ref-type="aff" rid="aff3"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-9322-2689</contrib-id><name-alternatives><name xml:lang="en"><surname>Fassakhov</surname><given-names>Rustem S.</given-names></name><name xml:lang="ru"><surname>Фассахов</surname><given-names>Рустэм Салахович</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD, Dr. Sci. (Med.), Professor</p></bio><bio xml:lang="ru"><p>д-р мед. наук, профессор</p></bio><email>farrus@mail.ru</email><xref ref-type="aff" rid="aff2"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">Kazan Research Institute of Epidemiology and Microbiology</institution></aff><aff><institution xml:lang="ru">Казанский научно-исследовательский институт эпидемиологии и микробиологии</institution></aff></aff-alternatives><aff-alternatives id="aff2"><aff><institution xml:lang="en">Kazan Federal University</institution></aff><aff><institution xml:lang="ru">Казанский (Приволжский) федеральный университет</institution></aff></aff-alternatives><aff-alternatives id="aff3"><aff><institution xml:lang="en">Kazan State Medical University</institution></aff><aff><institution xml:lang="ru">Казанский государственный медицинский университет</institution></aff></aff-alternatives><pub-date date-type="preprint" iso-8601-date="2024-03-22" publication-format="electronic"><day>22</day><month>03</month><year>2024</year></pub-date><pub-date date-type="pub" iso-8601-date="2024-04-15" publication-format="electronic"><day>15</day><month>04</month><year>2024</year></pub-date><volume>21</volume><issue>1</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>43</fpage><lpage>54</lpage><history><date date-type="received" iso-8601-date="2023-10-18"><day>18</day><month>10</month><year>2023</year></date><date date-type="accepted" iso-8601-date="2024-03-06"><day>06</day><month>03</month><year>2024</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2024, Pharmarus Print Media</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2024, Фармарус Принт Медиа</copyright-statement><copyright-year>2024</copyright-year><copyright-holder xml:lang="en">Pharmarus Print Media</copyright-holder><copyright-holder xml:lang="ru">Фармарус Принт Медиа</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/" start_date="2026-04-15"/></permissions><self-uri xlink:href="https://rusalljournal.ru/raj/article/view/16463">https://rusalljournal.ru/raj/article/view/16463</self-uri><abstract xml:lang="en"><p><italic>BACKGROUND: </italic>The effector capabilities of humoral immunity are determined not only by the amount of specific antibodies produced in response to an antigenic effect, but also by their qualitative characteristics, which include avidity ― the total strength of binding to the antigen, which determines the duration and effectiveness of post-infectious immunity to SARS-CoV-2.</p> <p><italic>AIM: </italic>Is a selective study of the quantity and avidity of IgG antibodies to SARS-CoV-2 over time among medical workers of a temporary infectious diseases hospital in Kazan ― convalescents of COVID-19, during the period from July 2020 to July 2021.</p> <p><italic>MATERIALS AND METHODS: </italic>Determination of IgG to the S antigen of SARS-CoV-2 by ELISA was carried out using the test system SARS-CoV-2-IgG quantitative-ELISA-BEST (Vector-Best, Russia) and expressed in BAU/ml (binding antibody units). Antibody avidity was determined using a 4.0 M urea solution and expressed as avidity indices. 1, 4 and 7 months after COVID-19 asymptomatic (<italic>n=</italic>34); mild severity (<italic>n=</italic>42); moderate severity (<italic>n=</italic>29); reinfected (<italic>n=</italic>34). When statistically processing the data, descriptive statistics methods and the Wilcoxon matched data test were used. Differences were considered significant at <italic>p &lt;</italic>0.05.</p> <p><italic>RESULTS: </italic>IgG avidity to SARS-CoV-2 depended on the severity of COVID-19. The highest rates of avidity indices were found in the group of those who had a moderate form of COVID-19. If in mild and asymptomatic forms there was a parallel decrease in avidity indices and IgG titer, then in moderate forms an increase in antibody titer was accompanied by a decrease in their avidity 4 months after the infection. 7 months after seroconversion, the IgG level decreased almost twofold, both in mild, asymptomatic and moderate forms. In the group of medical workers who had COVID-19 repeatedly, the initially low levels of avidity indices and antibody titers increased in parallel, while avidity indices after 7 months did not decrease, but remained high. Differences in avidity indices determined the subsequent formation of different trends in the development of the humoral immune response, which were mainly characterized by an uneven decrease in IgG and persistence of IgM antibodies for more than 1 month.</p> <p><italic>CONCLUSIONS: </italic>The research results expand the understanding of the mechanisms of formation of the humoral immune response and the avidity of IgG antibodies against SARS-CoV-2 in the risk group ― medical workers. The level of humoral immunity decreases in the first six months and varies depending on the severity of COVID-19. The data obtained can be used to identify categories of increased risk of SARS-CoV-2 infection among healthcare workers, make decisions about immunorehabilitation and revaccination against COVID-19.</p></abstract><trans-abstract xml:lang="ru"><p>Обоснование. Эффекторные возможности гуморального иммунитета определяются не только количеством вырабатываемых в ответ на антигенное воздействие специфических антител, но и их качественными характеристиками, к которым относится авидность ― суммарная сила связывания с антигеном, определяющая продолжительность и эффективность постинфекционного иммунитета к SARS-CoV-2.</p> <p>Цель ― выборочное изучение количества и авидности IgG антител к SARS-CoV-2 в динамике у медицинских работников временного инфекционного госпиталя Казани ― реконвалесцентов COVID-19 в период с июля 2020 по июль 2021 года.</p> <p>Материалы и методы. Определение IgG антител к S-антигену SARS-CoV-2 методом иммуноферментного анализа (ИФА) проводили с использованием тест-системы «SARS-CoV-2-IgG количественный-ИФА-БЕСТ» (АО «Вектор-Бест», Россия) и выражали в единицах связывающих антител (BAU/ml). Авидность антител определяли с использованием раствора 4,0 М мочевины и выражали в индексах авидности через 1, 4 и 7 месяцев после перенесённой бессимптомно (<italic>n=</italic>34), в лёгкой (<italic>n=</italic>42) или средней степени тяжести (<italic>n=</italic>29) коронавирусной инфекции COVID-19 и у реинфицированных (<italic>n=</italic>34). При статистической обработке данных использовали методы описательной статистики, тест Уилкоксона сопряжённых данных. Различия считались значимыми при <italic>р &lt;</italic>0,05.</p> <p>Результаты. Авидность IgG антител к SARS-CoV-2 зависела от тяжести COVID-19. Наиболее высокие показатели индекса авидности выявлены в группе перенёсших среднетяжёлую форму. Если при лёгкой и бессимптомной формах наблюдалось параллельное снижение индекса авидности и титра IgG антител, то при среднетяжёлой форме рост титра антител сопровождался снижением их авидности через 4 месяца после перенесённой инфекции. Через 7 месяцев после сероконверсии уровень IgG антител снижался практически двукратно как при лёгкой, бессимптомной, так и среднетяжёлой форме. В группе медицинских работников, перенёсших COVID-19 повторно, исходно низкие показатели индекса авидности и титров антител нарастали параллельно, при этом индекс авидности через 7 месяцев не снижался, а сохранялся высоким. Различия в индексах авидности обусловливали формирование в последующем разных трендов гуморального иммунного ответа, которые в основном характеризовались неравномерным снижением IgG антител и сохранением IgМ в течение более чем 1 месяца.</p> <p>Заключение. Результаты исследований расширяют представление о механизмах формирования гуморального иммунного ответа и авидности IgG антител к SARS-CoV-2 в группе риска ― у медицинских работников. Уровень гуморального иммунитета снижается в первые полгода и различается в зависимости от степени тяжести перенесённой коронавирусной инфекции СOVID-19. Полученные данные могут быть использованы для выявления категорий повышенного риска инфицирования SARS-CoV-2 среди медицинских работников, принятия решения об иммунореабилитации и ревакцинации против COVID-19.</p></trans-abstract><kwd-group xml:lang="en"><kwd>COVID-19</kwd><kwd>SARS-CoV-2</kwd><kwd>antibody avidity</kwd><kwd>healthcare workers</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>COVID-19</kwd><kwd>SARS-CoV-2</kwd><kwd>авидность антител</kwd><kwd>медицинские работники</kwd></kwd-group><funding-group/></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><citation-alternatives><mixed-citation xml:lang="en">Briko NI, Kagramanyan IN, Nikiforov VV, et al. Pandemic COVID-19. Prevention Measures in the Russian Federation. Epidemiology and Vaccinal Prevention. 2020;19(2):4–12. doi: 10.31631/2073-3046-2020-19-2-4-12</mixed-citation><mixed-citation xml:lang="ru">Брико Н.И., Каграманян И.Н., Никифоров В.В., и др. Пандемия COVID-19. Меры борьбы с ее распространением в Российской Федерации // Эпидемиология и вакцинопрофилактика. 2020. Т. 19, № 2. C. 4–12. doi: 10.31631/2073-3046-2020-19-2-4-12</mixed-citation></citation-alternatives></ref><ref id="B2"><label>2.</label><citation-alternatives><mixed-citation xml:lang="en">Kudryashova AM, Manuylov VA, Murzina AA, et al. Dynamics in maturation of SARS-CoV-2 RBD-specific IgG antibody avidity depending on immunization timeframe and type. Russ J Infection Immunity. 2023;13(1):67–74. doi: 10.15789/2220-7619-DIM-2049</mixed-citation><mixed-citation xml:lang="ru">Кудряшова А.М., Мануйлов В.А., Мурзина А.А., и др. Динамика матурации авидности IgG-антител к RBD SARS-CoV-2 в зависимости от срока и типа иммунизации // Инфекция и иммунитет. 2023. Т. 13, № 1. C. 67–74. doi: 10.15789/2220-7619-DIM-2049</mixed-citation></citation-alternatives></ref><ref id="B3"><label>3.</label><citation-alternatives><mixed-citation xml:lang="en">Popova AYu, Ezhlova EB, Melnikova AA, et al. Herd immunity of SARS-CoV-2 among the population of Kalinigrad region amid the COVID-19 epidemic. J Infectology. 2020;12(5):62–71. doi: 10.22625/2072-6732-2020-12-5-62-71</mixed-citation><mixed-citation xml:lang="ru">Попова А.Ю., Ежлова Е.Б., Мельникова А.А., и др. Популяционный иммунитет к SARS-COV-2 населения Калиниградской области в эпидемический сезон COVID-19 // Журнал инфектологии. 2020. Т. 12, № 5. С. 62–71. doi: 10.22625/2072-6732-2020-12-5-62-71</mixed-citation></citation-alternatives></ref><ref id="B4"><label>4.</label><citation-alternatives><mixed-citation xml:lang="en">Bauer G. The potential significance of high avidity immunoglobulin G (IgG) for protective immunity towards SARS-CoV-2. Int J Infect Dis. 2021;106:61–64. doi: 10.1016/j.ijid.2021.01.061</mixed-citation><mixed-citation xml:lang="ru">Bauer G. The potential significance of high avidity immunoglobulin G (IgG) for protective immunity towards SARS-CoV-2 // Int J Infect Dis. 2021. Vol. 106. P. 61–64. doi: 10.1016/j.ijid.2021.01.061</mixed-citation></citation-alternatives></ref><ref id="B5"><label>5.</label><citation-alternatives><mixed-citation xml:lang="en">Underwood РA. Problems and pitfalls with measurement of antibody affinity using solid phase binding in the ELISA. J Immunol Methods. 1993;164(1):119–130. doi: 10.1016/0022-1759(93)90282-c</mixed-citation><mixed-citation xml:lang="ru">Underwood P.A. Problems and pitfalls with measurement of antibody affinity using solid phase binding in the ELISA // J Immunol Methods. 1993. Vol. 164, N 1. P. 119–130. doi: 10.1016/0022-1759(93)90282-c</mixed-citation></citation-alternatives></ref><ref id="B6"><label>6.</label><citation-alternatives><mixed-citation xml:lang="en">Dauner J, Pan Y, Hildesheim A, et al. Development and application of a GuHCl-modified ELISA to measure the avidity of anti-HPV L1 VLP antibodies in vaccinated individuals. Mol Cell Probes. 2012;26(2):73–80. doi: 10.1016/j.mcp.2012.01.002</mixed-citation><mixed-citation xml:lang="ru">Dauner J., Pan Y., Hildesheim A., et al. Development and application of a GuHCl-modified ELISA to measure the avidity of anti-HPV L1 VLP antibodies in vaccinated individuals // Mol Cell Probes. 2012. Vol. 26, N 2. P. 73–80. doi: 10.1016/j.mcp.2012.01.002</mixed-citation></citation-alternatives></ref><ref id="B7"><label>7.</label><citation-alternatives><mixed-citation xml:lang="en">Dimitrov J, Lacroix-Desmazes S, Kaveri V. Important parameters for evaluation of antibody avidity by immunosorbent assay. Anal Biochem. 2011;418(1):149–151. doi: 10.1016/j.ab.2011.07.007</mixed-citation><mixed-citation xml:lang="ru">Dimitrov J., Lacroix-Desmazes S., Kaveri V. Important parameters for evaluation of antibody avidity by immunosorbent assay // Anal Biochem. 2011. Vol. 418, N 1. P. 149–151. doi: 10.1016/j.ab.2011.07.007</mixed-citation></citation-alternatives></ref><ref id="B8"><label>8.</label><citation-alternatives><mixed-citation xml:lang="en">Benner SE, Patel EU, Laeyendecker O, et al. SARS-CoV-2 antibody avidity responses in COVID-19 patients and convalescent plasma donors. J Infect Dis. 2020;222(12):1974–1984. doi: 10.1093/infdis/jiaa581</mixed-citation><mixed-citation xml:lang="ru">Benner S.E., Patel E.U., Laeyendecker O., et al. SARS-CoV-2 antibody avidity responses in COVID-19 patients and convalescent plasma donors // J Infect Dis. 2020. Vol. 222, N 12. P. 1974–1984. doi: 10.1093/infdis/jiaa581</mixed-citation></citation-alternatives></ref><ref id="B9"><label>9.</label><citation-alternatives><mixed-citation xml:lang="en">Tang J, Grubbs G, Lee Y, et al. Impact of convalescent plasma therapy on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibody profile in coronavirus disease 2019 (COVID-19) patients. Clin Infect Dis. 2022;74(2):327–334. doi: 10.1093/cid/ciab317</mixed-citation><mixed-citation xml:lang="ru">Tang J., Grubbs G., Lee Y., et al. Impact of convalescent plasma therapy on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibody profile in coronavirus disease 2019 (COVID-19) patients // Clin Infect Dis. 2022. Vol. 74, N 2. P. 327–334. doi: 10.1093/cid/ciab317</mixed-citation></citation-alternatives></ref><ref id="B10"><label>10.</label><citation-alternatives><mixed-citation xml:lang="en">Interim guidelines "Prevention, diagnosis and treatment of new coronavirus infection (COVID-19)" Ministry of Health of the Russian Federation. Version 6. (28.04.2020). 2020. 165 р. (In Russ).</mixed-citation><mixed-citation xml:lang="ru">Временные методические рекомендации «Профилактика, диагностика и лечение новой коронавирусной инфекции (COVID-19)» Министерства здравоохранения Российской Федерации. Версия 6 (28.04.2020). 2020. 165 с.</mixed-citation></citation-alternatives></ref><ref id="B11"><label>11.</label><citation-alternatives><mixed-citation xml:lang="en">Piccoli L, Park Y, Tortorici M, et al. Mapping neutralizing and immunodominant sites on the SARS-CoV-2 spike receptor-binding domain by structure-guided high-resolution serology. Cell. 2020;183(4):1024–1042.e21. doi: 10.1016/j.cell.2020.09.037</mixed-citation><mixed-citation xml:lang="ru">Piccoli L, Park Y, Tortorici M, et al. Mapping neutralizing and immunodominant sites on the SARS-CoV-2 spike receptor-binding domain by structure-guided high-resolution serology // Cell. 2020. Vol. 183, N 4. P. 1024–1042.e21. doi: 10.1016/j.cell.2020.09.037</mixed-citation></citation-alternatives></ref><ref id="B12"><label>12.</label><citation-alternatives><mixed-citation xml:lang="en">Toptygina AP, Afridonova ZE, Zakirov RSh, Semikina EL. Maintaining immunological memory to the SARS-CoV-2 virus during COVID-19 pandemic. Russ J Infection Immunity. 2023;13(1):55–66. doi: 10.15789/2220-7619-MIM-2009</mixed-citation><mixed-citation xml:lang="ru">Топтыгина А.П., Афридонова З.Э., Закиров Р.Ш., Семикина Е.Л. Поддержание иммунологической памяти к вирусу SARS-CoV-2 в условиях пандемии // Инфекция и иммунитет. 2023. Т. 13, № 1. C. 55–66. doi: 10.15789/2220-7619-MIM-2009</mixed-citation></citation-alternatives></ref><ref id="B13"><label>13.</label><citation-alternatives><mixed-citation xml:lang="en">Reshetnikova ID, Agafonova EV, Khakimov NM, et al. Features of the formation of seroprevalence to SARS-CoV2 in the population of the republic of tatarstan during the spread of COVID-19. Epidemiology and Vaccinal Prevention. 2023;22(1):13–21. doi: 10.31631/2073-3046-2023-22-1-13-21</mixed-citation><mixed-citation xml:lang="ru">Решетникова И.Д., Агафонова Е.В., Хакимов Н.М., и др. Особенности гуморального иммунного ответа к SARS-CoV-2 у медицинских работников временного инфекционного госпиталя // Эпидемиология и вакцинопрофилактика. 2023. Т. 22, № 1. С. 13–21. doi: 10.31631/2073-3046-2023-22-1-13-21</mixed-citation></citation-alternatives></ref><ref id="B14"><label>14.</label><citation-alternatives><mixed-citation xml:lang="en">Lynch KL, Whitman JD, Lacanienta NP, et al. Magnitude and kinetics of anti-SARS-CoV-2 antibody responses and their relationship to disease severity. Clin Infect Dis. 2020;72(2):301–308. doi: 10.1093/cid/ciaa979</mixed-citation><mixed-citation xml:lang="ru">Lynch K.L., Whitman J.D., Lacanienta N.P., et al. Magnitude and kinetics of anti-SARS-CoV-2 antibody responses and their relationship to disease severity // Clin Infect Dis. 2020. Vol. 72, N 2. P. 301–308. doi: 10.1093/cid/ciaa979</mixed-citation></citation-alternatives></ref><ref id="B15"><label>15.</label><citation-alternatives><mixed-citation xml:lang="en">Stephens DS, McElrath MJ. COVID-19 and the path to immunity. JAMA. 2020;324(13):1279–1281. doi: 10.1001/jama.2020.16656</mixed-citation><mixed-citation xml:lang="ru">Stephens D.S., McElrath M.J. COVID-19 and the path to immunity // JAMA. 2020. Vol. 324, N 13. P. 1279–1281. doi: 10.1001/jama.2020.16656</mixed-citation></citation-alternatives></ref><ref id="B16"><label>16.</label><citation-alternatives><mixed-citation xml:lang="en">Wang C, Li W, Drabek D, et al. A human monoclonal antibodyblocking SARS-CoV-2 infection. Nat Commun. 2020;11(1):2251. doi: 10.1038/s41467-020-16256-y</mixed-citation><mixed-citation xml:lang="ru">Wang C, Li W, Drabek D, et al. A human monoclonal antibodyblocking SARS-CoV-2 infection // Nat Commun. 2020. Vol. 11, N 1. P. 2251. doi: 10.1038/s41467-020-16256-y</mixed-citation></citation-alternatives></ref><ref id="B17"><label>17.</label><citation-alternatives><mixed-citation xml:lang="en">Long Q, Liu B, Deng H, et al. Antibody responses to SARS-CoV-2 in patients with COVID-19. Nat Med. 2020;26(6):845–848. doi: 10.1038/s41591-020-0897-1</mixed-citation><mixed-citation xml:lang="ru">Long Q, Liu B, Deng H, et al. Antibody responses to SARS-CoV-2 in patients with COVID-19 // Nat Med. 2020. Vol. 26, N 6. P. 845–848. doi: 10.1038/s41591-020-0897-1</mixed-citation></citation-alternatives></ref><ref id="B18"><label>18.</label><citation-alternatives><mixed-citation xml:lang="en">Andreev IV, Nechay KO, Andreev AI, et al. Post-vaccination and post-infection humoral immune response to the SARS-CoV-2 infection. Immunologiya. 2022;43(1):18–32. doi: 10.33029/0206-4952-2022-43-1-18-32</mixed-citation><mixed-citation xml:lang="ru">Андреев И.В., Нечай К.О., Андреев А.И., и др. Поствакцинальный и постинфекционный гуморальный иммунный ответ на инфекцию SARS-CoV-2 // Иммунология. 2022. Т. 43, № 1. С. 18–32. doi: 10.33029/0206-4952-2022-43-1-18-32</mixed-citation></citation-alternatives></ref><ref id="B19"><label>19.</label><citation-alternatives><mixed-citation xml:lang="en">Nordström P, Ballin M, Nordström A. Risk of SARS-CoV-2 reinfection and COVID-19 hospitalisation in individuals with natural and hybrid immunity: A retrospective, total population cohort study in Sweden. Lancet Infect Dis. 2022;22(6):781–790. doi: 10.1016/S1473-3099(22)00143-8</mixed-citation><mixed-citation xml:lang="ru">Nordström P., Ballin M., Nordström A. Risk of SARS-CoV-2 reinfection and COVID-19 hospitalisation in individuals with natural and hybrid immunity: A retrospective, total population cohort study in Sweden // Lancet Infect. Dis. 2022. Vol. 22, N 6. P. 781–790. doi: 10.1016/S1473-3099(22)00143-8</mixed-citation></citation-alternatives></ref><ref id="B20"><label>20.</label><citation-alternatives><mixed-citation xml:lang="en">Turner JS, Kim W, Kalaidina E, et al. SARS-CoV-2 infection induces long-lived bone marrow plasma cells in humans. Nature. 2021;595(7867):421–425. doi: 10.1038/s41586-021-03647-4</mixed-citation><mixed-citation xml:lang="ru">Turner J.S., Kim W., Kalaidina E., et al. SARS-CoV-2 infection induces long-lived bone marrow plasma cells in humans // Nature. 2021. Vol. 595, N 7867. P. 421–425. doi: 10.1038/s41586-021-03647-4</mixed-citation></citation-alternatives></ref><ref id="B21"><label>21.</label><citation-alternatives><mixed-citation xml:lang="en">Toptygina AP, Mamaeva TA, Alioshkin VA. Peculiarities of specific humoral measles immune response. Russ J Infection Immunity. 2013;3(3):243–250. doi: 10.15789/2220-7619-2013-3-243-250</mixed-citation><mixed-citation xml:lang="ru">Топтыгина А.П., Мамаева Т.А., Алешкин В.А. Особенности специфического гуморального иммунного ответа против вируса кори // Инфекция и иммунитет. 2013. Т. 3, № 3. С. 243–250. doi: 10.15789/2220-7619-2013-3-243-250</mixed-citation></citation-alternatives></ref><ref id="B22"><label>22.</label><citation-alternatives><mixed-citation xml:lang="en">Manuylov V, Burgasova O, Borisova O, et al. Avidity of IgG to SARS-CoV-2 RBD as a prognostic factor for the severity of COVID-19 reinfection. Viruses. 2022;14(3):617. doi: 10.3390/v14030617</mixed-citation><mixed-citation xml:lang="ru">Manuylov V., Burgasova O., Borisova O., et al. Avidity of IgG to SARS-CoV-2 RBD as a prognostic factor for the severity of COVID-19 reinfection // Viruses. 2022. Vol. 14, N 3. P. 617. doi: 10.3390/v14030617</mixed-citation></citation-alternatives></ref></ref-list></back></article>
